Clinical Trial Update: Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of Interferon alfa and sargramostim in newly diagnosed chronic-phase chronic myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Interferon Alfa (interferon alfa)
• sargramostim (sargramostim)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Leukemia | Phase 2 | Status: TERMINATED